Today, Health Canada authorized Novavax’s Nuvaxovid COVID-19 vaccine for the prevention of COVID-19 in adults 18 years of age and older. This is the fifth COVID-19 vaccine authorized in Canada. After a thorough, independent review of the evidence, the Department has determined that this vaccine meets Canada’s stringent safety, efficacy and quality requirements. Nuvaxovid is a protein-based vaccine that is administered as a two-dose regimen of 5 mcg per dose, 21 days apart. Based on the clinical trials overall, Nuvaxovid is 90% effective at preventing symptomatic COVID-19 and 100% effective at …